INmune Bio, Inc. (NASDAQ:INMB) Given Consensus Rating of “Buy” by Analysts

Shares of INmune Bio, Inc. (NASDAQ:INMB) have been given a consensus recommendation of “Buy” by the six ratings firms that are covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $22.80.

A number of equities research analysts recently commented on the stock. Scotiabank upped their price target on shares of INmune Bio from $22.00 to $23.00 and gave the company a “sector outperform” rating in a report on Tuesday, February 11th. Rodman & Renshaw assumed coverage on shares of INmune Bio in a research note on Tuesday, January 28th. They set a “buy” rating and a $23.00 price objective for the company. Maxim Group raised their target price on INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Finally, RODMAN&RENSHAW upgraded INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in shares of INmune Bio during the fourth quarter valued at approximately $2,221,000. Praetorian PR LLC boosted its stake in INmune Bio by 61.0% during the 3rd quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock valued at $4,209,000 after purchasing an additional 295,800 shares during the last quarter. Dauntless Investment Group LLC bought a new stake in shares of INmune Bio in the 4th quarter worth $896,000. Millennium Management LLC raised its stake in shares of INmune Bio by 43.9% in the fourth quarter. Millennium Management LLC now owns 291,327 shares of the company’s stock worth $1,360,000 after purchasing an additional 88,823 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of INmune Bio by 73.3% during the fourth quarter. Renaissance Technologies LLC now owns 185,800 shares of the company’s stock valued at $868,000 after purchasing an additional 78,600 shares in the last quarter. 12.72% of the stock is owned by hedge funds and other institutional investors.

INmune Bio Stock Performance

Shares of INmune Bio stock opened at $8.02 on Monday. INmune Bio has a 52-week low of $4.32 and a 52-week high of $12.96. The company has a fifty day moving average of $7.67 and a 200-day moving average of $6.22. The stock has a market capitalization of $177.82 million, a price-to-earnings ratio of -3.68 and a beta of 1.93.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.